Enterprise Value
-19.88M
Cash
100.8M
Avg Qtr Burn
-23.02M
Short % of Float
6.55%
Insider Ownership
14.58%
Institutional Own.
45.49%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Korsuva IV (CR845 IV) Details Pruritus with chronic kidney disease , Kidney disease | Approved Quarterly sales | |
Oral Korsuva (difelikefalin) (CR845) Details Pruritus with chronic kidney disease , Chronic kidney disease | Phase 3 Update | |
Oral Korsuva (difelikefalin) (CR845) Details Chronic pruritus, Pruritus associated with notalgia paresthetica | Phase 2/3 Data readout | |
Oral Korsuva (difelikefalin) (CR845) Details Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder | Failed Discontinued | |
Oral Korsuva (difelikefalin)(CR845) Details Inflammatory disease, Skin disease/disorder, Atopic dermatitis, Atopic pruritus | Failed Discontinued |